| Title: | The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank |
| Journal: | Pharmaceuticals |
| Published: | 11 Sep 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37765085/ |
| DOI: | https://doi.org/10.3390/ph16091277 |
| URL: | https://www.mdpi.com/1424-8247/16/9/1277/pdf?version=1694405645 |
| Citations: | 6 (6 in last 2 years) as of 8 Aug 2024 |
Publication 9590
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly. CYP2C19 is a key enzyme involved in the metabolism of several drugs, including SSRIs. Variations in the CYP2C19 gene are associated with differential metabolic activity, and thus differential SSRI exposure; accordingly, the CYP2C19 genotype may affect the therapeutic response and clinical outcomes, though existing evidence of this link is not entirely consistent. Therefore, we analysed data from the UK Biobank, a large, deeply phenotyped prospective study, to investigate the effects of CYP2C19 metaboliser phenotypes on several clinical outcomes derived from primary care records, including multiple measures of antidepressant switching, discontinuation, duration, and side effects. In this dataset, 24,729 individuals were prescribed citalopram, 3012 individuals were prescribed escitalopram, and 12,544 individuals were prescribed sertraline. Consistent with pharmacological expectations, CYP2C19 poor metabolisers on escitalopram were more likely to switch antidepressants, have side effects following first prescription, and be on escitalopram for a shorter duration compared to normal metabolisers. CYP2C19 poor and intermediate metabolisers on citalopram also exhibited increased odds of discontinuation and shorter durations relative to normal metabolisers. Generally, no associations were found between metabolic phenotypes and proxies of response to sertraline. Sensitivity analyses in a depression subgroup and metabolic activity scores corroborated results from the primary analysis. In summary, our findings suggest that CYP2C19 genotypes, and thus metabolic phenotypes, may have utility in determining clinical responses to SSRIs, particularly escitalopram and citalopram, though further investigation of such a relationship is warranted.</p>
8 Authors
- Win Lee Edwin Wong
- Chiara Fabbri
- Benjamin Laplace
- Danyang Li
- Roos van Westrhenen
- Cathryn M. Lewis
- Gavin Stewart Dawe
- Allan H. Young
1 Application
| Application ID | Title |
|---|---|
| 56514 | Stratification of health outcomes in mood disorders |
Enabling scientific discoveries that improve human health